King Pharmaceuticals KG Legacy Reinsurance — Intangible Assets, Net (Including Goodwill)

Similar metrics at other companies

AXSReinsurance — Intangible Assets, Net (Including Goodwill)

$0—

ACGLReinsurance — Goodwill and intangible assets

$93M-8.8%

AXSInsurance — Intangible Assets, Net (Including Goodwill)

$230.15M-4.0%

CBGlobal Reinsurance — Goodwill

$371M—

BRK.AInsurance And Other — Intangible Assets Net Excluding Goodwill

$34.28B-0.2%

WALCorporate & Other — Goodwill and intangible assets, net

$0—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetIncludingGoodwill.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's legacy reinsurance — intangible assets, net (including goodwill).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — intangible assets, net (including goodwill)?: King Pharmaceuticals (KG) reported legacy reinsurance — intangible assets, net (including goodwill) of $8.51M in Q1 2026.
What does legacy reinsurance — intangible assets, net (including goodwill) mean?: The carrying value of non-physical assets, including goodwill, acquired through business combinations within the Legacy Reinsurance segment. It reflects the long-term value attributed to brand, customer relationships, or market position beyond tangible book value.